Letter to the editor: 'Emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa'

Expert Opin Emerg Drugs. 2022 Dec;27(4):445-447. doi: 10.1080/14728214.2022.2152202.

Authors

Anastasios Georgiadis¹, Alexander J Smith^{2

3}, Michel Michaelides^{2

4}, Stuart Naylor¹, Alexandria Forbes¹

Affiliations

¹ MeiraGTx Holdings plc, New York, USA.
² UCL Institute of Ophthalmology, University College London, London, UK.
³ Centre for Gene Therapy and Regenerative Medicine, School of Basic and Medical Biosciences, Kings College London, London, UK.
⁴ Moorfields Eye Hospital, London, UK.

PMID: 36562396
DOI: 10.1080/14728214.2022.2152202

No abstract available

Publication types

Letter
Comment

MeSH terms

Eye Proteins / genetics
Genetic Therapy
Humans
Mutation
Retinitis Pigmentosa* / genetics
Retinitis Pigmentosa* / therapy

Substances

Eye Proteins
RPGR protein, human